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DE-71 is a commercial mixture of mostly
tetra- and penta-brominated diphenyl ethers
(PBDEs), which has been used extensively
as a flame retardant (Agency for Toxic
Substances and Disease Registry 2004). DE-
71 and other similar commercial mixtures
(known collectively as pentaBDE) were used
almost exclusively as ﬂame retardants in ﬂexi-
ble polyurethane foam, a major component
of bed mattresses and upholstered products.
Production of DE-71 ceased in 2004 (U.S.
Environmental Protection Agency 2006), the
same year that use of pentaBDE and other
PBDE commercial mixtures was banned by
the European Union (2003).
PBDEs are very stable compounds, and
they are not chemically bonded to the mater-
ial they are intended to protect from burning.
As a result, they are widely found in environ-
mental media (Hites 2004; Law et al. 2006)
and can be found in human blood and milk
(Furst 2006; Gomara et al. 2007; Lind et al.
2003; Main et al. 2007; Mazdai et al. 2003;
Schecter et al. 2003). Some of the PBDE
congeners most commonly found in human
samples are BDE-47, BDE-99, and BDE-153
(Hites 2004; Gomara et al. 2007; Main et al.
2007; Mazdai et al. 2003). Two of these same
congeners, the tetrabrominated BDE-47 and
the pentabrominated BDE-99, are the main
components of DE-71 (36% and 44% by
weight, respectively); the hexabrominated
BDE-153 is a minor component of DE-71
(4% by weight) (Qiu et al. 2007). 
The prevalence of PBDEs in human tissue
is of concern because these compounds are
known to alter behavior, thyroid-hormone
signaling, and sexual development in animals.
Eriksson and colleagues found permanent
aberrations in spontaneous behavior in
rodents after developmental exposure to
BDE-47 (Eriksson et al. 2001), BDE-99
(Eriksson et al. 2006; Viberg et al. 2004), or
BDE-153 (Viberg et al. 2003). Serum thyrox-
ine (T4) was signiﬁcantly decreased in several
different experimental models and by differ-
ent pentaBDE mixtures: in rats exposed to
DE-71 either prenatally or postnatally (Ellis-
Hutchings et al. 2006; Stoker et al. 2004;
Zhou et al. 2002); in American kestrels (Falco
sparverius) exposed in ovo to a mixture of
BDE-47, BDE-99, BDE-100 and BDE-153
(Fernie et al. 2005); and in adult female rats
exposed to the commercial pentaBDE mix-
ture Bromkal 70-5 DE (Darnerud et al.
2007). The effect of PBDEs on T4 levels may
require metabolic activation because
hydroxylated PBDEs, but not the non-
hydroxylated congeners, are able to bind
human transthyretin in vitro (Meerts et al.
2000). Other effects of pentaBDE mixtures
or their congeners in experimental animals
suggest estrogenic or antiandrogenic activity.
In rats, developmental exposure to BDE-99
affected the regulation of estrogen target
genes (Ceccatelli et al. 2006), impaired
spermatogenesis (Kuriyama et al. 2005), and
decreased circulating sex steroids and reduced
anogenital distance in males (Lilienthal et al.
2006). Male rats exposed to DE-71 on post-
natal days 23–53 had reduced seminal vesicle
and ventral prostate weights and delayed
puberty (Stoker et al. 2004).
PBDEs are suspected to behave as estro-
gens because of the similarity of their chemical
structures and properties to other xeno-
estrogens, mainly the polychlorinated
biphenyls (PCBs) (Hooper and McDonald
2000; Meerts et al. 2001; Pijnenburg et al.
1995). We have shown that DE-71 has weak
estrogenic activity in vivo and in vitro
(Mercado-Feliciano and Bigsby 2008).
Because hydroxylated metabolites of a struc-
turally similar class of halogenated aromatic
pollutants, the PCBs, exert estrogenic effects
(Carpenter 2006; Vakharia and Gierthy 2000),
it may be reasonable to expect that hydroxy-
lated forms of PBDEs would also be estro-
genic. Others have shown that some PBDE
congeners and certain synthetically hydroxy-
lated congeners could exert estrogenic effects in
cultured cells (Hamers et al. 2006; Meerts
et al. 2001). In a recent in vivo study, BDE-47
had uterotrophic effects in immature rats
(Dang et al. 2007), suggesting in vivo activa-
tion of this otherwise nonestrogenic PBDE
(Meerts et al. 2001). 
We previously reported that DE-71 is
metabolized in the mouse to produce
hydroxylated metabolites (Qiu et al. 2007)
and that it had mild estrogenic activity in the
same animals (Mercado-Feliciano and Bigsby
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BACKGROUND: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment and
are suspected endocrine disruptors. We previously identiﬁed six hydroxylated metabolites of PBDE
(OH-PBDEs) in treated mice.
OBJECTIVE: We tested the hypothesis that OH-PBDEs would interact with and alter activity of
estrogen receptor-α (ER-α).
METHODS: We tested estrogenicity using two assays: 3H-estradiol (3H-E2) displacement from
recombinant ER-α, and induction of reporter gene (ERE-luciferase) in cultured cells. We incubated
the PBDE mixture DE-71 with rat liver microsomes and tested the resultant metabolite mixture for
estrogenic activity. We also determined relative estrogenic potential of individual hydroxylated
PBDE congeners. 
RESULTS: Reporter gene activity was increased by DE-71 that had been subjected to microsomal
metabolism. DE-71 did not displace E2 from ER-α, but all six of the OH-PBDE metabolites did.
para-Hydroxylated metabolites displayed a 10- to 30-fold higher afﬁnity for ER-α compared with
ortho-hydroxylated PBDEs, and one produced a maximal effect 30% higher than that produced by
E2. Coadministration of E2 and DE-71, or certain of its metabolites, yielded reporter activity greater
than either chemical alone. Two ortho-OH-PBDEs were antiestrogenic in the reporter assay.
CONCLUSIONS: The observations—that the DE-71 mixture did not displace 3H-E2 from ER-α,
while the hydroxylated metabolites did—suggest that the weak estrogenic effects of DE-71 are due
to metabolic activation of individual congeners. However, the behavior of DE-71 and its metabo-
lites, when co-administered with E2, suggest a secondary, undetermined mechanism from classical
ER-α activation.
KEYWORDS: cytochrome P450, DE-71, endocrine disruptors, ERE-luciferase, estrogens, mice,
ovariectomized, PBDEs, polybrominated diphenyl ethers. Environ Health Perspect 116:1315–1321
(2008). doi:10.1289/ehp.11343 available via http://dx.doi.org/ [Online 27 May 2008]2008). In the present study, our goal was to
determine if DE-71 or its in vivo metabolites
could induce estrogenic signaling though
ER-α. 
Materials and Methods
Test chemicals. We purchased dimethyl sul-
foxide (DMSO) and estradiol [1,3,5(10)-estra-
triene-3,17β-diol; E2] from Sigma Chemical
Co. (St. Louis, MO). The PBDE congener
mixture DE-71 was a gift from the Great
Lakes Chemical Corporation (West Lafayette,
IN); the congener composition was previously
described by Qiu et al. (2007). The individual
hydroxylated metabolites of PBDE [4-OH-
2,2´,4-tribromodiphenyl (4´-OH-BDE-17);
2´-OH-2,4,4´-tribromodiphenyl
(2´-HO-BDE-28); 4-HO-2,2´,3,4´-tetra-
bromodiphenyl (4-OH-BDE-42); 3-OH-
2,2´,4,4´-tetrabromodiphenyl
(3-OH-BDE-47); 6-OH-2,2´,4,4´-tetra-
bromodiphenyl (6-OH-BDE-47); and
4´-OH-2,2´,4,5´-tetrabromodiphenyl
(4´-OH-BDE-49)] were synthesized as
described by Marsh et al. (2004) and were
gifts from G. Marsh (Stockholm University,
Stockholm, Sweden). We purchased the
brominated phenols 2,4-dibromophenol
(2,4-DBP) and 2,4,5-tribromophenol
(2,4,5-TBP) from Cambridge Isotope
Laboratories (Cambridge, MA). DMSO was
used as primary solvent for all chemicals, and
the DMSO solutions were further diluted in
cell culture media for treatments.
Cells and culture conditions. MDA-
MB-231 breast cancer cells (Cailleau et al.
1978) obtained from ATCC (American Type
Culture Collection; Manassas, VA) and
BG1Luc4E2 ovarian cancer cells, a gift from
M. Denison (University of California, Davis,
CA), were used in estrogen bioassays.
BG1LucE2 cells are BG-1 ovarian cancer cells
(Geisinger et al. 1989) stably transfected with
an estrogen-responsive plasmid (Rogers and
Denison 2000). Most cell culture media and
supplements were purchased from Gibco/
Invitrogen (Carlsbad, CA), except bovine
growth serum (BGS; Hyclone, Logan, UT) and
geneticin (G418; Sigma). Most charcoal-strip-
ping reagents and endotoxin-free water were
purchased from Sigma-Aldrich (St. Louis, MO)
except Dulbecco’s phosphate-buffered saline
(DPBS; Mediatech Inc., Herndon, VA).
MDA-MB-231 cells were maintained in
growth medium (GM): minimum essential
media (MEM) supplemented with L-glutamine
(2 mM), nonessential amino acids (0.1 mM),
HEPES buffer (10 mM), 0.4 pg/mL insulin,
and 5% vol/vol BGS]. BG1Luc4E2 cells were
maintained in BG1-GM: alpha-MEM supple-
mented with HEPES buffer (10 mM),
geneticin (0.4 g/L) and 10% vol/vol BGS. Basal
medium (BM) for MDA-MB-231 cells con-
sisted of a formulation similar to GM, except
that phenol red–free MEM and 3% charcoal-
stripped BGS were used. BM for BG1Luc4E2
cells (BG1-BM) consisted of phenol red–free
Dulbecco’s modified Eagle media: Nutrient
Mixture F12 (DMEM:F12; Gibco/Invitrogen)
supplemented with HEPES buffer (10 mM)
and 10% vol/vol charcoal-stripped BGS. BGS
was stripped of estrogenic activity by methods
described previously (Biswas and Vonderhaar
1987; Lippman et al. 1976). 
Estrogen response element-luciferase (ERE-
luc) assays. We used two ERE-luciferase
reporter gene systems: one transiently trans-
fected and the other an established stably
transfected cell line. For the transient system,
ER-negative MDA-MB-231 breast cancer cells
were plated in BM. Two days later cells were
transfected using Tfx-20 (Promega, Madison,
WI) with expression vectors for ER-α (HEG0;
from P. Chambon, Université Louis Pasteur,
Illkrich, France), the estrogen-responsive ﬁre-
ﬂy luciferase reporter construct ERE2-pS2-luc
(Long et al. 2001), and the control Renilla
luciferase reporter construct pRL-TK
(Promega). Cells were treated with test chemi-
cals 1 hr after transfection, and assayed for
luciferase activity after 18 hr. Results are
expressed as the ratio of firefly luciferase to
Renilla luciferase. For the stable reporter sys-
tem, ER-positive BG1Luc4E2 ovarian cancer
cells (Rogers and Denison 2000) were incu-
bated in BG1-BM for 5 days before treatment;
cells were then assayed for luciferase activity
18 hr after addition of the test compound.
In vitro generation of microsomal metabo-
lites. We incubated DE-71 or E2 with liver
microsomes to obtain microsomal metabolites,
following a procedure adapted from Bulger
et al. (1978). Glucose-6-phosphate, glucose-6-
phosphate dehydrogenase (G6PD) and
β-nicotinamide adenine dinucleotide phos-
phate (oxidized form, NADP+) were pur-
chased from Sigma-Aldrich. DE-71 (1 mM) or
E2 (1 µM) were incubated for 24 hr with
female rat liver microsomes (BD Biosciences
Gentest, Woburn, MA) in a buffer that
included an NADPH-generating system
(50 mm Tris buffer, pH 7.5, 5 mM MgCl2,
12 mM glucose-6-phosphate, 0.4 mM
NADP+, 2 units G6PD) in loose-capped tubes
at 37°C with shaking. The incubation mixture
was then centrifuged at 105,000 relative cen-
trifugal force (RCF) at 4°C for 1 hr to remove
microsomes. The hydroxylated organic fraction
was extracted from the supernatant by solid-
state extraction with ethanol elution using Sep-
Pak Plus C18 cartridges (Waters Corp.;
Milford, MA), then evaporated to dryness
in vacuo and reconstituted in a volume of
DMSO that would yield 10 mM PBDE or
10 µM estradiol, assuming 100% recovery.
This extraction procedure was adapted from
Yoshihara et al. (2004).
Recombinant ER-α binding assay. Vehicle
or test chemicals were incubated with 1 nM
tritiated E2 (3H-E2; Amersham Biosciences,
Buckinghamshire, UK) and 0.6 nM recombi-
nant ER-α (Panvera/Invitrogen, Madison, WI)
in TE buffer (10 mM Tris, 1 mM EDTA,
pH 7.5) at 4°C overnight. Hydroxylapatite
(60% in TE buffer) was added, mixed well,
and incubated for 15 min at room tempera-
ture. The resulting slurry was washed three
times by centrifugation at 3,000 RCF at
4°C with TE buffer changed. Bound ligand
was extracted by incubation of the slurry
with absolute ethanol at 30°C for 10 min.
Tritium (3H) decay (counts per minute) was
measured by liquid scintillation in a Beckman
LS 5000 TD counter (Beckman-Coulter Inc.,
Fullerton, CA). 
Statistics. All statistics were performed
using GraphPad Prism, version 3.0a, for
Macintosh (GraphPad Software, San Diego
CA). For each analysis, we determined
whether groups had unequal variances by
Bartlett’s test. Group averages with equal vari-
ances were compared to each other either by
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Table 1. Blood serum concentrations [μM (mean ±
SE)] of phenolic metabolites found in mice after
DE-71 treatment. 
Compound Vehicle control DE-71
2,4-DBP 0.01 ± 0.02 0.29 ± 0.09
2,4,5-TBP 0.001 ± 0.002 0.24 ± 0.09
4´-OH-BDE-17 ND 0.04 ± 0.02
2´-OH-BDE-28 0.0002 ± 0.0005 0.03 ± 0.01
4-OH-BDE-42 0.002 ± 0.01 0.36 ± 0.24
3-OH-BDE-47 ND 0.11 ± 0.05
6-OH-BDE-47 ND 0.04 ± 0.02
4´-OH-BDE-49 0.001 ± 0.002 0.08 ± 0.04
DE-71a < 0.02 3.9 ± 0.8
ND, not detected. Mice were treated with 50 mg/kg/day
DE-71 (per os) for 34 days. Concentrations were deter-
mined by gas chromatographic mass spectrometry analy-
sis. Modiﬁed from Qiu et al. (2007).
aAll non-OH congeners. 
Figure 1. ERE-luciferase induction by microsomal
metabolites of DE-71. Incubations with an incom-
plete NADPH generating system (lacking NADP+)
were run in parallel and served as the negative
control. The incubation products were tested in
ERE-luciferase assays. One representative assay is
shown; results are presented as mean ± SD (n = 4).
The results are representative of three similar
assays. 
**p < 0.01, and #p < 0.001 compared with vehicle control.
##p < 0.001 compared with the same treatment without the
complete NADPH generating system.
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t-test with Welch’s correction. Groups treated
with DE-71 or E2 alone were compared with
vehicle controls, and groups cotreated with
DE-71 and E2 were compared with controls
treated with E2 alone. All values are expressed
as mean ± SD or SE as indicated. We consid-
ered groups statistically different if p < 0.05
by ANOVA with Tukey posttest or t-test
(two-tailed). Dose–response studies were also
subjected to regression analysis using a
sigmoidal curve ﬁtting model: 
Response = 
minimum + ([maximum – minimum] 
÷ {1 + 10[log(EC50) – log(dose)] × Hillslope}),
where EC50 is the median effective concentra-
tion. The modeled curve is shown in ﬁgures if
R2 > 0.8. 
Results
In vitro microsomal metabolism increases
estrogenic character of DE-71. To determine
whether microsomal metabolism could
increase estrogenic activity, we incubated
DE-71 with female rat microsomes, with or
without a complete NADPH generating sys-
tem. The incubation product was then tested
in ERE-luciferase assays, using either the tran-
sient transfection system with MDA-MB-231
cells or the stably transfected ER-α–positive
BG1Luc4E2 cells. At 10–5 M, DE-71
induced little ERE-luciferase activity when it
was incubated in the buffer lacking an
NADPH generating capacity (without
NADP+; negative control), but the product
of the complete incubation buffer produced a
4-fold increase in luciferase (Figure 1).
Microsomal incubation decreased the activity
of E2 by 78%, an expected result because
hydroxylation decreases the activity of E2
(Martucci and Fishman 1993). Furthermore,
the level of activity of the extract from the E2
incubated without NADP+ indicates that
recovery of compound by the extraction
methods used and in three separate microso-
mal incubation experiments was 66–98%.
Phenolic metabolites found in blood of
mice after treatment with DE-71. In a previ-
ous study (Qiu et al. 2007), we examined
blood serum from BALB/c mice that had
been treated with DE-71 for 34 days and
quantified identifiable phenolic metabolites
that included two brominated phenols and six
hydroxylated brominated diphenyl ethers
(Table 1). These ﬁndings raise the possibility
that the estrogenic effects seen earlier in mice
and in culture (Mercado-Feliciano and Bigsby
2008) were due to the metabolites and not
necessarily the original DE-71 congeners.
DE-71 and its phenolic metabolites acti-
vate the ERE. E2 induces ERE-luciferase at
concentrations above 10–13 M in the stably
transfected BG1Luc3E2 reporter cell culture
system (Figure 2), with an EC50 in the pico-
molar range (Table 2). Neat DE-71 and the
metabolites found in mice were tested using
BG1Luc3E2 cells to determine if they were
able to activate ERE-mediated gene transcrip-
tion (Figure 2), and their potencies and effec-
tiveness were compared to that of E2
(Table 2). The potencies of each test com-
pound were estimated by determining the
compound’s own EC50 from its own maximal
effect, and also by calculating its relative
estrogenic potency determined from the con-
centration required to produce an effect
equivalent to E2’s EC50. 
DE-71 was able to significantly induce
ERE-luciferase at test concentrations ≥ 5 ×
10–5 M, reaching the same effectiveness as E2
at 10–4 M (Figure 2B). The calculated EC50
for DE-71 was 3.7 × 10–5 M. Because the
maximal effect of DE-71 was very close to the
maximal effect of E2, its EC50 (3.7 × 10–5 M)
and its estrogen equivalency potency (EEP;
DE-71 metabolites are weak ER-α ligands
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Figure 2. ERE-luciferase induction by E2 (A), DE-71 (B), and the OH-BDEs 4´-OH-BDE-17 (C), 4-OH-BDE-42 (D), 4´-OH-BDE-49 (E), 2´-OH-BDE-28 (F), 3-OH-
BDE-47 (G), 6-OH-BDE-47 (H), 2,4-DBP (I), and 2,4,5-TBP (J). See “Material and Methods” for details. Each curve for an OH-BDE represents the mean of 3–6 inde-
pendent dose–response studies, except 6-OH-BDE-47, for which only 2 assays were performed. Curves for DE-71 and E2 are the mean of 12 and 8 independent
dose–response studies, respectively. Error bars indicate SE. All values are normalized to vehicle control (DMSO = 1). Modeled data for E2 (dashed blue line) and
DE-71 (dotted line) are shown in all OH-BDE charts for comparison. Modeled data for each OH-BDE are shown as a solid line. 
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Br
Br3.9 × 10–5 M) were similar. One metabolite,
4´-OH-BDE-17 was clearly more potent than
DE-71, with an EC50 in the micromolar
range (Table 2). 4´-OH-BDE-17 had a rela-
tive estrogenic potency approximately 10-fold
that of DE-71, and it was more effective than
DE-71 or E2, reaching an estimated maximal
effect 30% higher than E2 (Figure 2C;
Table 2). 4´-OH-BDE-49 had an EC50 simi-
lar to that of DE-71 but a much lower effi-
cacy; its maximal effect did not even reach the
EC50 for E2 (Figure 2E; Table 2). Another
para-hydroxylated metabolite, 4-HO-
BDE-42, appears to have been more potent
than DE-71, but because of limited availabil-
ity of this compound, the analysis was not
carried out with a sufﬁcient span of concen-
trations to allow an accurate estimate of the
EC50 (Figure 2D).
DE-71 phenolic metabolites displace 3H-E2
from ER-α. We assessed the ability of the
metabolites found in mouse blood to displace
3H-E2 from recombinant ER-α, and results are
summarized in Figure 3 and Table 3. Neither
the DE-71 mixture nor the bromophenol
metabolites 2,4-DBP and 2,4,5-TBP were able
to displace 3H-E2 from ER-α (Figure 3B,I,J).
All of the hydroxylated BDEs displaced 3H-E2
from ER-α, but their relative binding afﬁnities
were very low (Table 3). Of the OH-BDEs
tested, the para-hydroxylated congeners (at
either the 4 or 4´ position) had a higher afﬁnity
for the estrogen receptor than 2-, 3-, or 6-OH-
BDEs. 4´-OH-BDE-17 and 4´-OH-BDE-49
were the most potent, with mean inhibitory
concentrations (IC50) in the micromolar range
(Figure 3C,D,E; Table 3). 6-OH-BDE-47,
Mercado-Feliciano and Bigsby
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Figure 3. Displacement of 1 nM 3H-E2 from recombinant ER-α in vitro by E2 (A), DE-71 (B), and the OH-BDEs 4´-OH-BDE-17 (C), 4-OH-BDE-42 (D), 4´-OH-BDE-49 (E),
2´-OH-BDE-28 (F), 3-OH-BDE-47 (G), 6-OH-BDE-47 (H), 2,4-DBP (I), and 2,4,5-TBP (J) found in mice (by the ER-α binding assay). Each curve for an OH-BDE repre-
sents the mean of 3–4 independent dose–response studies, except for 4-OH-BDE-49, 6-OH-BDE-47, and the bromophenols only 2 assays were performed. Curves
for DE-71 and E2 are the mean of 6 and 11 independent dose–response studies, respectively. Error bars indicate SE. All values are normalized to vehicle control
(DMSO = 1). Modeled data for E2 (dashed blue line) and DE-71 (dotted line) are shown in all OH-BDE charts for comparison. Modeled data for each OH-BDE are
shown as a solid line. 
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Table 2. Potency and efﬁcacy estimates of DE-71 metabolites in the ERE-luciferase assay.
Relative estrogen Fold-induction Relative
Compound EC50
a (M) EEP  (M)b potencyc (ratio) at EC50 effectd (ratio)
E2 1.2 × 10–12 — 1.00 3.3 1.00
DE-71 3.7 × 10–5 3.9 × 10–5 3.1 × 10–8 3.4 1.03
2,4-DBP No effect — — — —
2,4,5-TBP No effect — — — —
4´-OH-BDE-17 4.7 × 10–6 3.5 × 10–6 3.4 × 10–7 4.3 1.30
2´-OH-BDE-28 NA NR — — —
4-OH-BDE-42 NA NA — NA NA
3-OH-BDE-47 NA NR — NA —
6-OH-BDE-47 No effect — — — —
4´-OH-BDE-49 1.3 × 10–5 NR — 1.2 0.36
Abbreviations: NA, not available because effect was insufﬁcient to calculate an EC50; NR, E2 EC50 not reached. All values
were estimated from curves derived in Figure 2.
aDetermined using the chemical’s own maximum effect set at 100%. bConcentration inducing the same luciferase activity
as the EC50 of E2. cRatio of the E2 EC50 to EEP. dTest chemical-to-E2 ratio of luciferase induction at EC50. 
Table 3. ER-α relative binding afﬁnities.
Compound IC50
a Relative afﬁnityb(%)
E2 6.9 × 10–10 100
DE-71 No  effect —
2,4-DBP No  effect —
2,4,5-TBP No  effect —
4´-OH-BDE-17 2.1 × 10–6 0.03
2´-OH-BDE-28 6.0 × 10–5 0.001
4-OH-BDE-42 1.4 × 10–5 0.005
3-OH-BDE-47 5.2 × 10–5 0.001
6-OH-BDE-47 1.1 × 10–5 0.001
4´-OH-BDE-49 2.3 × 10–6 0.03
aThe concentration of test compound yielding 50% dis-
placement of 3H-E2 from receptor, calculated based on
data shown in Figure 3. bRelative affinity was calculated
as E2 IC50 ÷ test chemical IC50 × 100.3-OH-BDE-47, and 2´-OH-BDE-28 had IC50
values one order of magnitude higher than the
para-OH-BDEs (Figure 3F,G,H; Table 3). In
general, the potency of each OH BDE dis-
placing 3HE 2 from ER-α correlates with their
ability to activate ERE-luciferase, and the con-
geners with the highest IC50 values induce very
little (3 OH-BDE 47) or no signiﬁcant ERE-
luciferase activity (2´-OH-BDE-28 and 6-OH-
BDE-47).
DE-71 phenolic metabolites modify ERE
activation by E2. Because DE-71 and several of
its hydroxylated metabolites were able to either
activate and/or displace 3H-E2 from ER-α, We
cotreated BG1Luc3E2 cells with 10–11 M E2
and one of the chemicals of interest to deter-
mine if the PBDEs were able to modify E2-
induced ERE-luciferase activity. The two
bromophenol metabolites found in mice,
2,4-DBP and 2,4,5-TBP, were not tested
because they had no signiﬁcant effect in either
the ERE-induction or the 3H-E2 displacement
assays. DE-71 induced ERE-luciferase beyond
the maximal effect of E2 alone (Figure 4B). The
same was true for 4´-OH-BDE-17 and 4´-OH-
BDE-49 (Figure 4C,E). Another PBDE tested,
4-OH-BDE-42, appeared to induce ERE-
luciferase above the E2 maximum, but the effect
was not statistically significant (Figure 4D).
The only meta-OH-PBDE tested, 3-OH-
BDE-47, was not estrogenic by itself but was
able to potentiate the ERE-luciferase induction
of E2 (Figures 2G and 4G). The two ortho-
hydroxylated BDE metabolites exhibited a
biphasic dose–response curve in the E2 cotreat-
ment assay. At high concentrations, 2´-OH-
BDE-28 and 6-OH-BDE-47 were able
to antagonize the effect of E2. 6-OH-BDE-47
was the more potent antagonist, showing an
effect at 5 × 10–6 M, whereas antagonism by
2´-OH-BDE-28 was observed only at 5 ×
10–5 M (Figure 4F,H). Both of these metabo-
lites also seem to potentiate the effect of
10–11 M E2 at lower concentrations in a man-
ner similar to other PBDEs tested, although
this effect was statistically signiﬁcant only for
2´-OH-BDE-28. However, because only DE-
71 and 2´-OH-BDE-28 were tested at a con-
centration of ≥ 5 × 10–5 M, it is possible that
other hydroxylated PBDEs have the same
biphasic behavior in the ERE-luciferase assay.
The protein content of the culture wells at the
time of harvest (not shown) indicated that there
was no toxicity produced by 6-OH-BDE-47 or
2´-OH-BDE-28 at these concentrations
(5–50 µM) when tested alone or in combina-
tion with E2. Interestingly, both OH-BDEs
found to be estrogen antagonists were able to
displace 3H-E2 from ER-α (Figure 3F,H), but
when administered alone they did not induce
signiﬁcant ERE-luciferase (Figure 2F,H).
Discussion 
PBDEs are suspected to behave as estrogens
because of the similarity of their chemical
structure to other xenobiotics, mainly the
PCBs (Crews et al. 1995; Ulbrich and
Stahlmann 2004; Winneke et al. 2002).
Furthermore, hydroxylated metabolites of
PCBs have been shown to exert estrogenic
effects (Blair et al. 2000; Kuiper et al. 1997).
Therefore, it may be reasonable to expect that
hydroxylated forms of PBDEs are also estro-
genic. Our previous ﬁndings indicate that the
PBDE mixture DE-71 is estrogenic in vitro
and in vivo, although much less potent than
E2 (Mercado-Feliciano and Bigsby 2008).
Here, we show estrogenic and antiestrogenic
effects of the phenolic metabolites of DE-71
by an interaction with ER-α. 
Meerts et al. (2001) tested 17 PBDE con-
geners for estrogenic activity in an ERE-
luciferase assay (ER-CALUX; Legler et al.
1999). Two of the congeners in DE-71,
BDE-28 and BDE-100, were mildly estro-
genic; BDE-100 was the most potent of the
PBDEs although not the most effective.
Using the same ER-CALUX bioassay,
Hamers et al. (2006) showed weak estrogenic
activity for the DE-71 congeners BDE-28,
BDE-47, and BDE-100, but not for the
pentaBDE mixture Bromkal 70-5DE. Results
from Meerts et al. (2001) and Hamers et al.
(2006) agree in the relative potency of these
chemicals, and both groups agree that the
EC50 for BDE-100 is in the micromolar
range. In the present study we showed that
DE-71 increased expression of ERE-luciferase
reporter gene in BG1Luc3E2 cells, with
potency similar to that of BDE-28 and
BDE-100 in the ER-CALUX assay (Hamers
et al. 2006; Meerts et al. 2001). The difference
between our ERE-luciferase results and those
of Hamers et al. (2006) can be accounted for
by the fact that we tested higher concentra-
tions. It may also be that the BG-1 cells we
used and the T47D cells of the ER-CALUX
assay differ in their ability to metabolically
activate the various PBDE congeners.
In the present study, we observed meta-
bolic activation of DE-71 to an estrogenic
product in vitro, and previous experiments
demonstrated that DE-71 congeners are
hydroxylated in the mouse (Qui et al. 2007), a
chemical modification that could increase
their estrogenic activity. In the in vitro experi-
ments, DE-71 was preincubated with rat liver
microsomes, imitating the classical experi-
ments by which Kupfer and Bulger demon-
strated the metabolic activation of the
DE-71 metabolites are weak ER-α ligands
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Figure 4. ERE-luciferase induction in BG1Luc4E2 cells after coteatment with E2. See “Material and Methods” for details. Squares indicate data for cotreatment with
10–11 M E2 and the speciﬁed chemical; data are normalized to the maximal effect of E2 (set at 1.0). Each curve is the mean of 3–5 independent dose–response studies,
except for 2-OH-BDE28, 6-OH-BDE47, and 4-OH-BDE49 for which only 2 assays were performed. Error bars indicate SE. Modeled data for E2-only dose–response (blue
dashed line) are shown in all charts for comparison. 
*p > 0.5; **p > 0.01; and #p > 0.001 compared with the maximal effect of E2 alone. 
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Kupfer and Bulger 1979). Preincubation of
DE-71 with microsomes under enzyme-acti-
vating conditions increased its estrogenic
activity. Mammalian liver microsomes are rich
in cytochrome P450 (CYP450), a group of
isoenzymes responsible for metabolism of
many endogenous and exogenous chemicals
including estrogens (reviewed by Bigsby et al.
2005). The biological activities of environ-
mental chemicals have been found to be either
increased or decreased by specific CYP450s
(Goldstein and Faletto 1993), and some of
these chemicals are known to be converted
into estrogens by CYP450 metabolism (Bulger
et al. 1978; Kohno et al. 2005; Kupfer and
Bulger 1979; Morohoshi et al. 2005). Based
on findings by Qui et al. (2007) and others
(Malmberg et al. 2005; Marsh et al. 2006),
the DE-71 congener BDE-47 seems to be the
source of activated OH-PBDEs in laboratory
rodents; BDE-47 itself has been found to have
little estrogenic activity (Hamers et al. 2006;
Meerts et al. 2001). Others have also found
OH-PBDEs in wild marine animals that
could be BDE-47 metabolites (Kelly 2006;
Verreault et al. 2005; Verreault et al. 2007).
However, the source of OH-BDEs in the
marine environment can be both natural and
anthropogenic, because some marine organ-
isms produce natural brominated compounds
(Vetter 2006).
We observed both estrogenic and anti-
estrogenic effects in our study. We found that
metabolites of DE-71 hydroxylated at the ortho
position could act as antiestrogens. Although
cotreatment with DE-71 produced a larger
effect than the maximal response to E2 in the
present study using a reporter gene assay, in
another bioassay, based on MCF-7 cell prolif-
eration, we observed both an agonist effect
when DE-71 was administered alone and an
antiestrogenic effect when coadministered with
E2 (Mercado-Feliciano and Bigsby 2008).
Because both MCF-7 cells and ovarian cancer
cells express CYP450 enzymes (Deloia et al.
2008; Leung et al. 2007; Peters et al. 2004), it
may be that the effects in cell proliferation and
gene expression were due to metabolites gener-
ated in culture. The difference in responses
between cell proliferation and reporter gene
assays could result from generation of different
metabolites in each assay due to differences in
treatment duration (10 days vs. 18 hr, respec-
tively) and/or the predominant CYP450 iso-
enzyme activities in each kind of tissue
(mammary vs. ovarian cancers). In addition,
the estrogenic activity seen by other investiga-
tors for individual congeners in reporter gene
bioassays (Hamers et al, 2006; Meerts et al.
2001) could be due to metabolic activation of
those compounds. Thus, it is likely that the
observed biological activity of DE-71 resulted
from the sum of estrogenic and antiestrogenic
activities of metabolites produced from
individual BDE congeners. 
Compounds may act as endocrine disrup-
tors through a number of mechanisms,
including indirectly by altering metabolism of
endogenous hormones. Hamers et al. (2008)
found that BDE-47 and several of the
OH-PBDE metabolites that we found to have
either estrogenic or antiestrogenic activity in
culture also inhibit estrogen sulfotransferases
(E2SULT) in vitro. Such an effect would
translate into an increased activity of adminis-
tered E2 and could explain the ability of
3-OH-BDE-47 to increase ERE-luciferase
expression above the level induced by E2
alone when BG-1Luc4E2 cells are cotreated
with both chemicals, even though 3-OH-
BDE-47 does not induce ERE-luciferase by
itself. However, the E2 dose used in cotreat-
ment with 3-OH-BDE-47 was already high
enough to reach the maximal effect in this
system; therefore, it is unlikely that making
more E2 available by inhibiting E2SULT
would increase ERE-luciferase signaling.
Furthermore, it is not known whether the
BG-1Luc4E2 cells express E2SULT, and we
observed no significant potentiation of the
estrogenic effect by 4-OH-BDE-42, another
metabolite that behaves as a potent inhibitor
of E2SULT in vitro. A weaker E2SULT
inhibitor, 6-OH-BDE-47, actually produced
an antiestrogenic effect in our system. Thus,
it is unlikely that altered E2SULT activity
explains the additional estrogenic effect pro-
duced by 3-OH-BDE-47.
The levels of DE-71 needed to have estro-
genic effects in our studies (micromolar
range) are much higher than the highest con-
centrations found so far in human blood
serum (0.1–5 nM; Mazdai et al. 2003).
However, there is little current information
on the levels of OH-PBDEs in human serum
or the role that human enzymes (especially
CYP450) may play in the formation of
DE-71 metabolites. Rodent tissues do not
have the same CYP450 activities as human
tissues (Bogaards et al. 2000); therefore, the
metabolites we found in mouse serum (Qui
et al. 2007) or those found by Marsh et al.
(2006) in rat feces may not be representative
of metabolites formed in humans. Several of
the PBDE metabolites we found in mice
(4´-OH-BDE-17, 6-OH-BDE-47, 3-OH-
BDE-47, and 4-OH-BDE-42) have been
found in human serum samples from children
working at a municipal waste disposal site
(Athanasiadou et al. 2008) at much lower
concentrations (< 0.1 nM) than are required
to cause estrogenic effects in culture (≥ 1µ M )
or associated with slight estrogenic effects in
mice (> 40 nM; Table 1) following approxi-
mately 1 month of treatment (Mercado-
Feliciano and Bigsby 2008). It is reasonable
to expect that PBDE exposure for municipal
waste workers is due in part to contact with
DE-71 and other pentaBDE mixtures in dis-
carded consumer products. However,
Athanasioadou et al. (2008) found an addi-
tional PBDE metabolite in humans, 4-OH-
BDE-90, that we did not observe in mice,
and our own unpublished studies indicate
that 5-OH-BDE-47 and 5´-OH-BDE-99 are
major metabolites in human blood (Qui
et al., in press); the estrogenic activity of these
compounds has not been tested.
In summary, the observations that the
DE-71 mixture does not displace 3H-E2 from
ER-α—while the hydroxylated metabolites
do—suggest that the weak estrogenic effects
of DE-71 are due to metabolic activation of
individual congeners. However, the behavior
of DE-71 and some of its metabolites when
coadministered with E2 suggest a secondary,
undetermined mechanism of action different
from classical ER-α activation.
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